Advertisement

Current Oncology Reports

, 20:64 | Cite as

Toxicity of Cancer Therapies in Older Patients

Integrative Care (C Lammersfeld, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Integrative Care

Abstract

Purpose of the Review

In clinical practice, older patients are often undertreated due to underrepresentation in clinical trials and fear of toxicity. Our objective was therefore to review toxicities that are specific to older cancer patients, to review risk factors in order to help physicians guide their decisions, and to review interventions that can be implemented in routine clinical practice to prevent toxicity induced by cancer therapies.

Recent Findings

On the whole, reviews report similar number and frequency as well as similar grade 3 or 4 adverse events between subjects older and younger than 65 years.

Summary

Yet patients included in clinical trials are often not representative of real-life patients and are often fit older cancer patients. Moreover, tolerance to the additive impact of multiple adverse effects is different between older and younger patients. And specific symptoms such as stomatitis may cause a series of consequences such as dehydration, denutrition, renal insufficiency, and adverse events of renally excreted drugs. Older patients are at high risk of toxicity due to many factors but mainly due to the prevalence of frailty in this population that has been estimated to be around 40% increasing the risk of chemotherapy intolerance. As a consequence, interventions must be implemented according to altered domains of comprehensive geriatric assessment in order to improve anticancer tolerance. These interventions are reviewed here.

Keywords

Older patients Neoplasms Adverse events Frailty Interventions 

Notes

Compliance with Ethical Standards

Conflict of Interest

Olivia Le Saux declares that she has no conflict of interest.

Claire Falandry has received research support through grants from Novartis, Pfizer, Chugai, Astellas, and Pierre Fabre, and has received compensation from Roche, Teva, Pfizer, Chugai, Janssen, and Astellas for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Ries LAG, Eisner MP, Kosary CL, et al. Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 2003. p. 1975–2000.Google Scholar
  2. 2.
    Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31:128–36.CrossRefPubMedGoogle Scholar
  3. 3.
    • Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol. 2015;26:1091–101. In a systematic review of 20 observational studies, the median reported prevalence of frailty and pre-frailty was 42% and 43% respectively. Treatment complications were more frequent in patients with frailty. Therefore, this review is in favor of performing a proper geriatric assessment of our patients in order to guide therapeutic decisions. CrossRefPubMedGoogle Scholar
  4. 4.
    Clough-Gorr KM, Stuck AE, Thwin SS, Silliman RA. Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol. 2010;28:380–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Le Saux O, Falandry C, Gan HK, et al. Inclusion of elderly patients in oncology clinical trials. Ann Oncol. 2016;27:1799–804.CrossRefPubMedGoogle Scholar
  6. 6.
    Shenoy P, Harugeri A. Elderly patients’ participation in clinical trials. Perspect Clin Res. 2015;6:184–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Swaminathan D, Swaminathan V. Geriatric oncology: problems with under-treatment within this population. Cancer Biol Med. 2015;12:275–83.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Hall PS, Lord SR, Collinson M, Marshall H, Jones M, Lowe C, et al. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). Br J Cancer. 2017;116:472–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kozuki T, Nogami N, Kitajima H, Iwasawa S, Sakaida E, Takiguchi Y, et al. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients TORG1015. BMC Cancer. 2016;16:306.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lim KH, Lee HY, Park SB, Song SY. Feasibility of modified FOLFOX in elderly patients aged ≥80 years with metastatic gastric cancer or colorectal cancer. Oncology. 2017;93:115–21.CrossRefPubMedGoogle Scholar
  11. 11.
    • Mariano C, Francl M, Pope J, Wong L, Lim HJ, Lohrisch C. Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials. Clin Breast Cancer. 2015;15:73–9. All breast cancer trials open from 1999 to 2012 at BCCA, Vancouver Center, were reviewed. Few older patients were enrolled in cytotoxic chemotherapy trials, but they experienced no more toxicity than did the younger patients. This review suggest that toxicity between older and younger patients is similar in terms of number and frequency. Yet, this review also highlights the fact that older patients are less represented in clinical trials evaluating chemotherapy therefore suggesting that patients included are fit and not representative of routine older patients. CrossRefPubMedGoogle Scholar
  12. 12.
    Verzoni E, de Braud F, Fabiani F, Grassi P, Testa I, Procopio G. Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. Future Oncol. 2013;9:1599–607.CrossRefPubMedGoogle Scholar
  13. 13.
    Heppenstall CP, Wilkinson TJ, Hanger HC, Frailty KS. dominos or deliberation? N Z Med J. 2009;122:42–53.PubMedGoogle Scholar
  14. 14.
    Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013;63:249–79.CrossRefPubMedGoogle Scholar
  15. 15.
    Templeton A, Brandle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol. 2008;19:824–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Quivy A, Daste A, Harbaoui A, Duc S, Bernhard JC, Gross-Goupil M, et al. Optimal management of renal cell carcinoma in the elderly: a review. Clin Interv Aging. 2013;8:433–42.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Lichtman SM, Hurria A, Cirrincione CT, Seidman AD, Winer E, Hudis C, et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol. 2012;23:632–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Ward PR, Wong MD, Moore R, Naeim A. Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study. J Geriatr Oncol. 2014;5:57–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Ciorba A, Bianchini C, Pelucchi S, Pastore A. The impact of hearing loss on the quality of life of elderly adults. Clin Interv Aging. 2012;7:159–63.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lin FR, Ferrucci L. Hearing loss and falls among older adults in the United States. Arch Intern Med. 2012;172:369–71.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lin FR, Yaffe K, Xia J, Xue QL, Harris TB, Purchase-Helzner E, et al. Hearing loss and cognitive decline in older adults. JAMA Intern Med. 2013;173:293–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc. 2012;60:1761–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Lichtman SM. Call for changes in clinical trial reporting of older patients with cancer. J Clin Oncol. 2012;30:893–4.CrossRefPubMedGoogle Scholar
  24. 24.
    • Laurent M, Paillaud E, Tournigand C, Caillet P, le Thuaut A, Lagrange JL, et al. Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study. Oncologist. 2014;19:275–82. In a prospective French study, older patients with solid malignancies referred to two geriatric oncology clinics between 2007 and 2010 were prospectively included. Planned cancer treatment was feasible in only 59.0% of cases for chemotherapy. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wedding U, Honecker F, Bokemeyer C, Pientka L, Höffken K. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control. 2007;14:44–56.CrossRefPubMedGoogle Scholar
  26. 26.
    Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, et al. Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of Tamoxifen and Letrozole, alone and in sequence. J Clin Oncol. 2016;34:2452–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008;26:1443–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Figer A, Perez-Staub N, Carola E, Tournigand C, Lledo G, Flesch M, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer. 2007;110:2666–71.CrossRefPubMedGoogle Scholar
  29. 29.
    Bajetta E, Ravaud A, Bracarda S, Négrier S, Szczylik C, Bellmunt Molins J, Moore N, Pisa P, Escudier BJ Efficacy and safety of first-line bevacizumab (BEV) plus interferon-a2a (IFN) in patients (pts) P65 years with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26. suppl:abstr 5095.Google Scholar
  30. 30.
    Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010;78:329–39.CrossRefPubMedGoogle Scholar
  33. 33.
    Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol. 2010;136:737–43.CrossRefPubMedGoogle Scholar
  34. 34.
    Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49:287–97.CrossRefPubMedGoogle Scholar
  35. 35.
    Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann Oncol. 2011;22:118–26.CrossRefPubMedGoogle Scholar
  36. 36.
    Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA, et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014;110:1125–32.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100:1454–63.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hutson TE, Osanto S, Calvo E, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma (mRCC) after disease progression on VEGFr- TKI therapy [abstract no. 11]. Presented at the 2010 Kidney Cancer Symposium; 2010 Oct 2; Chicago (IL).Google Scholar
  39. 39.
    Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi A, Maio M, di Guardo L, et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res. 2014;33:30.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Freeman M, Weber J. Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma. J Immunother Cancer. 2015;3(Suppl 2):133.CrossRefGoogle Scholar
  41. 41.
    Rockwood K. Frailty andits definition: a worthy challenge. J Am Geriatr Soc. 2005;53:1069–70.CrossRefPubMedGoogle Scholar
  42. 42.
    Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.CrossRefPubMedGoogle Scholar
  43. 43.
    Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc. 2006;54:991–1001.CrossRefPubMedGoogle Scholar
  44. 44.
    Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16:1795–800.CrossRefPubMedGoogle Scholar
  45. 45.
    Hilpert F, du Bois A, Greimel ER, Hedderich J, Krause G, Venhoff L, et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer—a study by the AGO OVAR Germany. Ann Oncol. 2007;18:282–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23:8597–605.CrossRefPubMedGoogle Scholar
  47. 47.
    Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808–15.CrossRefPubMedGoogle Scholar
  48. 48.
    Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100:1058–67.CrossRefPubMedGoogle Scholar
  49. 49.
    Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat. 2008;107:443–50.CrossRefPubMedGoogle Scholar
  50. 50.
    Wauthier V, Verbeeck RK, Calderon PB. The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem. 2007;14:745–57.CrossRefPubMedGoogle Scholar
  51. 51.
    Bolignano D, Mattace-Raso F, Sijbrands EJ, Zoccali C. The aging kidney revisited: a systematic review. Ageing Res Rev. 2014;14:65–80.CrossRefPubMedGoogle Scholar
  52. 52.
    Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48:9–17.CrossRefPubMedGoogle Scholar
  53. 53.
    Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med. 1997;13:169–83.PubMedGoogle Scholar
  54. 54.
    Chassany O, Urien S, Claudepierre P, et al. Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol. 1996;38:571–3.CrossRefPubMedGoogle Scholar
  55. 55.
    Kumar GN, Walle UK, Bhalla KN, Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol. 1993;80:337–44.PubMedGoogle Scholar
  56. 56.
    Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet. 2003;42:779–91.CrossRefPubMedGoogle Scholar
  57. 57.
    Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet. 2003;42:1213–42.CrossRefPubMedGoogle Scholar
  58. 58.
    Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev. 2007;65:S173–6.CrossRefPubMedGoogle Scholar
  59. 59.
    Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol. 2011;11:289–95.CrossRefPubMedGoogle Scholar
  60. 60.
    Candore G, Grimaldi MP, Listi F, Ferlazzo V, Colonna-Romano G, Motta M, et al. Prevalence of non organ-specific autoantibodies in healthy centenarians. Arch Gerontol Geriatr Suppl. 2002;8:75–80.CrossRefPubMedGoogle Scholar
  61. 61.
    Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol. 1987;69:557–65.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Schwandt A, Wood LS, Rini B, Dreicer R. Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther. 2009;2:51–61.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Tariman JD, Berry DL, Cochrane B, Doorenbos A, Schepp KG. Physician, patient, and contextual factors affecting treatment decisions in older adults with cancer and models of decision making: a literature review. Oncol Nurs Forum. 2012;39:E70–83.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    de Glas NA, Hamaker ME, Kiderlen M, de Craen AJM, Mooijaart SP, van de Velde CJH, et al. Choosing relevant endpoints for older breast cancer patients in clinical trials: an overview of all current clinical trials on breast cancer treatment. Breast Cancer Res Treat. 2014;146:591–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Bungay H, Cappello R. As long as the doctors know what they are doing’: trust or ambivalence about patient information among elderly men with prostate cancer? Eur J Cancer Care (Engl). 2009;18:470–6.CrossRefGoogle Scholar
  66. 66.
    Simon H, Saghatchian M, Mouysset JL et al. Results from an observational study (NORA) with oral Navelbine in metastatic breast cancer: a sub-analysis in elderly patients. JGO 3 suppl 1: S41-S42.Google Scholar
  67. 67.
    • Biganzoli L, Lichtman S, Michel JP, Papamichael D, Quoix E, Walko C, et al. Oral single-agent chemotherapy in older patients with solid tumours: a position paper from the International Society of Geriatric Oncology (SIOG). Eur J Cancer. 2015;51:2491–500. This position paper from the International Society of Geriatric Oncology states that for older cancer patients in general, metronomic chemotherapy combines good tolerability with acceptable activity. CrossRefPubMedGoogle Scholar
  68. 68.
    Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, Krypciak S, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol. 2011;29:3636–42.CrossRefPubMedGoogle Scholar
  69. 69.
    Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–52.CrossRefPubMedGoogle Scholar
  70. 70.
    Morello E, Sandri R, Monfardini S. Enough rehabilitation for our elderly cancer patients? Eur J Cancer. 2008;44:2338–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Wells JL, Seabrook JA, Stolee P, Borrie MJ, Knoefel F. State of the art in geriatric rehabilitation. Part II: clinical challenges. Arch Phys Med Rehabil. 2003;84:898–903.CrossRefPubMedGoogle Scholar
  72. 72.
    Wells JL, Seabrook JA, Stolee P, Borrie MJ, Knoefel F. State of the art in geriatric rehabilitation. Part I: review of frailty and comprehensive geriatric assessment. Arch Phys Med Rehabil. 2003;84:890–7.CrossRefPubMedGoogle Scholar
  73. 73.
    Flood KL, Carroll MB, Le CV, et al. Geriatric syndromes in elderly patients admitted to an oncology-acute care for elders unit. J Clin Oncol. 2006;24:2298–303.CrossRefPubMedGoogle Scholar
  74. 74.
    • Kalsi T, Babic-Illman G, Ross PJ, Maisey NR, Hughes S, Fields P, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 2015;112:1435–44. In a comparative study of two cohorts of older patients (aged 70+ years) undergoing chemotherapy in a London Hospital, older patients were more likely to complete cancer treatment as planned (odds ratio (OR) 4.14 (95% CI: 1.50–11.42), P=0.006) and fewer required treatment modifications (OR 0.34 (95% CI: 0.16–0.73), P=0.006). In conclusion, geriatrician-led interventions were associated with improved chemotherapy tolerance and should be implemented in routine. CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Aapro M, Johnson J. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours. Gerontology. 2005;51:287–96.CrossRefPubMedGoogle Scholar
  76. 76.
    Repetto L, Carreca I, Maraninchi D, et al. Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. Crit Rev Oncol Hematol. 2003;45:123–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017;7:1–12.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M. International Society of Geriatric Oncology. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer. 2007;43:852–8.CrossRefPubMedGoogle Scholar
  79. 79.
    Cohen HJ. A model for the shared care of elderly patients with cancer. J Am Geriatr Soc. 2009;57(Suppl 2):S300–2.CrossRefPubMedGoogle Scholar
  80. 80.
    Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis. 2010;53:88–93.CrossRefPubMedGoogle Scholar
  81. 81.
    van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010; CD005006.Google Scholar
  82. 82.
    Chlebowski RT, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF, et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep. 1980;64:47–51.PubMedGoogle Scholar
  83. 83.
    Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133–9.CrossRefPubMedGoogle Scholar
  84. 84.
    Mishra SI, Scherer RW, Snyder C, Geigle P, Gotay C. Are exercise programs effective for improving health-related quality of life among cancer survivors? A systematic review and meta-analysis. Oncol Nurs Forum. 2014;41:E326–42.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Li F, Harmer P, Fisher KJ, McAuley E, Chaumeton N, Eckstrom E, et al. Tai Chi and fall reductions in older adults: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2005;60:187–94.CrossRefPubMedGoogle Scholar
  86. 86.
    Lonardi S, Bortolami A, Stefani M, Monfardini S. Oral anticancer drugs in the elderly: an overview. Drugs Aging. 2007;24:395–410.CrossRefPubMedGoogle Scholar
  87. 87.
    Mislang AR, Wildes TM, Kanesvaran R, Baldini C, Holmes HM, Nightingale G, et al. Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treat Rev. 2017;57:58–66.CrossRefPubMedGoogle Scholar
  88. 88.
    Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, et al. Review of therapeutic drug monitoring of anticancer drugs part two—targeted therapies. Eur J Cancer. 2014;50:2020–36.CrossRefPubMedGoogle Scholar
  89. 89.
    Paci A, Veal G, Bardin C, Levêque D, Widmer N, Beijnen J, et al. Review of therapeutic drug monitoring of anticancer drugs part 1—cytotoxics. Eur J Cancer. 2014;50:2010–9.CrossRefPubMedGoogle Scholar
  90. 90.
    Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34.CrossRefPubMedGoogle Scholar
  91. 91.
    Launay-Vacher V, Spano JP, Janus N, Gligorov J, Ray-Coquard I, Oudard S, et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol. 2009;70:124–33.CrossRefPubMedGoogle Scholar
  92. 92.
    Mohile SG, Velarde C, Hurria A, Magnuson A, Lowenstein L, Pandya C, et al. Geriatric assessment-guided care processes for older adults: a Delphi consensus of geriatric oncology experts. J Natl Compr Cancer Netw. 2015;13:1120–30.CrossRefGoogle Scholar
  93. 93.
    Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for high-age patients (CRASH) score. Cancer. 2012;118:3377–86.CrossRefPubMedGoogle Scholar
  94. 94.
    Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457–65.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(557):565.Google Scholar
  96. 96.
    Zhang LL, Wang SZ, Chen HL, Yuan AZ. Tai Chi exercise for cancer-related fatigue in patients with lung cancer undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manag. 2016;51:504–11.CrossRefGoogle Scholar
  97. 97.
    Gilbert T, Bosquet A, Thomas-Anterion C, et al. Assessing capacity to consent for research in cognitively impaired older patients. Clin Interv Aging. 2017;12:1553–63.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Zerillo JA, Goldenberg BA, Kotecha RR et al. Interventions to improve oral chemotherapy safety and quality: a systematic review. JAMA Oncol 2017.Google Scholar
  99. 99.
    Moth EB, Vardy J, Blinman P. Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer. Expert Rev Gastroenterol Hepatol. 2016;10:1321–40.CrossRefPubMedGoogle Scholar
  100. 100.
    Goldzweig G, Baider L, Andritsch E, Rottenberg Y. Hope and social support in elderly patients with cancer and their partners: an actor-partner interdependence model. Future Oncol. 2016;12:2801–9.CrossRefPubMedGoogle Scholar
  101. 101.
    Bourdel-Marchasson I, Blanc-Bisson C, Doussau A, Germain C, Blanc JF, Dauba J, et al. Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial. PLoS One. 2014;9:e108687.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Ingram SS, Seo PH, Sloane R, Francis T, Clipp EC, Doyle ME, et al. The association between oral health and general health and quality of life in older male cancer patients. J Am Geriatr Soc. 2005;53:1504–9.CrossRefPubMedGoogle Scholar
  103. 103.
    Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7:346–53.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Sharp JW, Blum D, Aviv L. Elderly men with cancer: social work interventions in prostate cancer. Soc Work Health Care. 1993;19:91–107.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Medical Oncology DepartmentCentre Hospitalier Lyon SudPierre-BéniteFrance
  2. 2.Geriatric Oncology DepartmentCentre Hospitalier Lyon SudPierre-BéniteFrance
  3. 3.CarMen biomedical research laboratory (Cardiovascular diseases, Metabolism, diabetology and Nutrition) INSERM UMR 1060Université de LyonOullinsFrance

Personalised recommendations